Sodium chloride 0.18% / Glucose 4% infusion 500ml bags
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Glucose + Sodium chloride
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
MHRA licensed products
View all licensed products for Glucose + Sodium chloride on the MHRA register
Sodium chloride 0.18% / Glucose 4% infusion 500ml Viaflo bags
Steriflex No.18 glucose 4% / sodium chloride 0.18% infusion 500ml bags
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Intravenous fluid therapy in children and young people in hospital (NG29)
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
Intravenous fluid therapy in adults in hospital (CG174)
Intravenous fluid therapy in children and young people in hospital (QS131)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Neonatal parenteral nutrition (NG154)
Cystic fibrosis: diagnosis and management (NG78)
Adrenal insufficiency: identification and management (NG243)
Acute kidney injury: prevention, detection and management (NG148)
Healthcare-associated infections: prevention and control in primary and community care (CG139)
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
Infection prevention and control (QS61)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 2 · 1966–2026
Showing the 50 most relevant studies, sorted by most relevant.
H. Heerspink, B. Perkins, D. Fitchett, et al.
Circulation, 2016
Machhiwala M, El-Andari R, Hassanzadeh P, et al.
2026
BackgroundEx vivo lung perfusion (EVLP) supports assessment and rehabilitation of donor lungs. It runs as a closed circuit, so electrolytes and metabolites accumulate over the duration of perfusion. This systematic review investigates the impact of various dialysis or perfusate exchange (PE) techniques on electrolyte balance, inflammation and lung function during EVLP.MethodsA literature search of PubMed and Embase was conducted from database inception to September 17, 2025. We included all articles describing human or animal studies that tested dialysis or PE during EVLP. Outcomes included electrolytes, lactate, pH, edema formation, lung performance characteristics, and inflammatory markers.ResultsFive studies met the inclusion criteria, one human and four porcine models, with a total of 57 subjects. Across studies, dialysis consistently improved solute clearance, lowering sodium, potassium, and chloride, while increasing calcium and glucose, reducing lactate accumulation, and maintaining physiologic pH. PE did not sustain physiologic pH and had limited impact on electrolyte homeostasis, with only transient effects on lactate. No differences were observed in lung function parameters including oxygenation, compliance, and airway pressure. Pro-inflammatory cytokine production was largely unchanged, however, interleukin (IL)-10 was elevated with dialysis in several studies.ConclusionDuring EVLP, dialysis stabilized acid-base status and metabolites. These biochemical gains did not translate into consistent improvements in oxygenation or compliance. Smaller dialysis membranes were associated with higher pulmonary artery pressure (PAP) and increased cytokine profile. Future studies should extend EVLP duration with perfusate clearance to evaluate whether perfusate clearance strategies provide additional benefits with longer duration preservation.
Abstract licence: CC BY-NC-ND
M. Packer, C. Wilcox, J. Testani
Circulation, 2023
Chienwichai K, Laipanngam P, Jiwakanon S, et al.
2026
Yancai Li, Yanmei Zhong, Yayun Zhang, et al.
Sensors and Actuators B-chemical, 2015
J. Lawitts, J. Biggers
Molecular Reproduction and Development, 1992
G. Kimura
Circulation journal : official journal of the Japanese Circulation Society, 2016
G. Kimura
Journal of the American Society of Hypertension : JASH, 2016
T. Flowers
Journal of Experimental Botany, 1972
Hongyan Xu, Chengkai Xia, Siyan Wang, et al.
Sensors and Actuators B: Chemical, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.